There are three pharmacological classes currently available for acromegaly management, to be used as monotherapy or in combination, namely somatostatin analogues (i.e., octreotide, lanreotide and pasireotide), the GH receptor antagonist pegvisomant and dopamine agonists (e.g., cabergoline), which are off-label used15,16. This evidence concerns the gene GHR and acromegaly.